Phase I Study of Anti-CD3 x Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer Patients

Background. New nontoxic targeted approaches are needed for patients with castrate resistant prostate cancer (CRPC). Our preclinical studies show that activated T cells (ATC) armed with anti-CD3 x anti-Her2 bispecific antibody (Her2Bi) kill prostate cancer cells lines, induce a Th(1) cytokine patter...

Descripción completa

Detalles Bibliográficos
Autores principales: Vaishampayan, Ulka, Thakur, Archana, Rathore, Ritesh, Kouttab, Nicola, Lum, Lawrence G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2015
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4352947/
https://www.ncbi.nlm.nih.gov/pubmed/25802762
http://dx.doi.org/10.1155/2015/285193

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4352947/
https://www.ncbi.nlm.nih.gov/pubmed/25802762
http://dx.doi.org/10.1155/2015/285193

Ejemplares similares